Thrombocytopenia in the Course of COVID-19 Infection

  • Noel Lorenzo-Villalba Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Abrar-Ahmad Zulfiqar Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Marc Auburtin Service de Médecine Interne, Centre Hospitalier d’Epinal, Epinal, France
  • Marie Helene Schuhmacher Service de Médecine Interne, Centre Hospitalier d’Epinal, Epinal, France
  • Alain Meyer Service de Rhumatologie, Hôpitaux Universitaires de Strasboug, Strasbourg, France
  • Yasmine Maouche Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Olivier Keller Service de Médecine Interne, Centre Hospitalier de Haguenau, Haguenau, France
  • Emmanuel Andres Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Keywords

COVID-19, thrombocytopenia, immune thrombocytopenia, immunoglobulins, eltrombopag

Abstract

We report three cases of severe thrombocytopenia during COVID-19 infection associated with either cutaneous purpura or mucosal bleeding. The initial investigations ruled out other causes of thrombocytopenia. Two of the patients were treated with intravenous immunoglobulins and eltrombopag, while the third recovered spontaneously. A good clinical and biological response was achieved in all patients leading to hospital discharge.

VIEW THE ENTIRE ARTICLE

References

  • Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020;506:145–148.

  • Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019;3:3829–3866.

  • Zhang Y, Xiao M, Zhang S, Xia P, Cao W. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382(17):e38.

  • Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;20:105949.

  • Audia S, Godeau B, Bonnotte B. Is there still a place for "old therapies" in the management of immune thrombocytopenia? Rev Med Interne 2016;37:43–49.

  • Jolicoeur P, Lamontagne L. Impairment of bone marrow pre-B and B cells in MHV3 chronically-infected mice. Adv Exp Med Biol 1995;380:193–195.

  • Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology 2005;10:101–105.

  • Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3:3780–3817.
  • Published: 2020-05-07

    Issue: Vol 7 No 6 (view)

    Section: Articles

    How to cite:
    Lorenzo-Villalba, N., Zulfiqar, A.-A., Auburtin, M., Schuhmacher, M. H., Meyer, A., Maouche, Y., Keller, O., & Andres, E. (2020). Thrombocytopenia in the Course of COVID-19 Infection. European Journal of Case Reports in Internal Medicine, 7(6). https://doi.org/https://doi.org/10.12890/2020_001702

    Most read articles by the same author(s)